14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
LVTX vs CELU: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
LVTX Captures Overall Composite Edge (67.0 BUY vs 42.9 HOLD), While CELU Leads 3–2 on Growth & Valuation Pillars
LVTX Overall Winner
6-Pillar Tally: LVTX 2 – 3 CELU (1 Tie)
Matrix Metrics: LVTX 7 – 1 CELU
As of Nov 20, 2026, LAVA Therapeutics N.V. (LVTX) captures the overall head-to-head institutional edge over Celularity Inc. (CELU) on higher Unified Composite conviction (67.0/100 BUY vs. 42.9/100 HOLD) after splitting the core matrix 7–1 (led by Growth & Scale, Profitability & Quality), while CELU wins 3–2 across the 6-pillar growth and valuation breakdown. LVTX trades at $1.74 (N/M Forward P/E, -431.9% operating margin) versus CELU at $0.46 (N/M Forward P/E, -254.0% operating margin).
Growth vs. Quality Trade-Off: LVTX earns the overall head-to-head edge with a stronger Unified Composite Score (67.0/100 BUY vs. CELU 42.9/100 HOLD) and -0.02β · 49% Vol risk profile, whereas CELU leads top-line expansion (-5.3% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: LVTX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3); meanwhile CELU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LVTX vs CELU. Trailing 12-month operating profitability (LVTX -431.9% vs CELU -254.0%) and valuation multiples (LVTX N/M vs CELU N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Pharmaceutical Preparations value chain with $45.8M market capitalization and -431.9% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
CELU Moat ProfileCyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.2M market capitalization and -254.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ LVTX vs CELU Key Questions & Quantitative Answers
As of Nov 20, 2026, LAVA Therapeutics N.V. (LVTX) captures the overall head-to-head institutional edge over Celularity Inc. (CELU) on higher Unified Composite conviction (67.0/100 BUY vs. 42.9/100 HOLD) after splitting the core matrix 7–1 (led by Growth & Scale, Profitability & Quality), while CELU wins 3–2 across the 6-pillar growth and valuation breakdown. LVTX trades at $1.74 (N/M Forward P/E, -431.9% operating margin) versus CELU at $0.46 (N/M Forward P/E, -254.0% operating margin). Growth vs. Quality Trade-Off: LVTX earns the overall head-to-head edge with a stronger Unified Composite Score (67.0/100 BUY vs. CELU 42.9/100 HOLD) and -0.02β · 49% Vol risk profile, whereas CELU leads top-line expansion (-5.3% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: LVTX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3); meanwhile CELU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
LVTX leads the Growth & Scale pillar: LVTX posts +1313.6% YoY revenue growth and +0.0% YoY earnings growth on $5.0M TTM revenue (100.0% gross margin, -431.9% operating margin), compared with CELU at -5.3% YoY revenue growth and -61.3% YoY earnings growth on $19M TTM revenue (19.2% gross margin, -254.0% operating margin). On trailing 12-month operating scale, LVTX generates $5.0M in USD-normalized revenue versus $19M for CELU. In operating R&D and SG&A reinvestment, LVTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CELU.
CELU screens cheaper on headline valuation multiples. LVTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.2x EV/Revenue (unreported EBITDA margin), whereas CELU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.7x EV/Revenue (-47.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LVTX (-101.5% ROE) versus CELU (-6367.2% ROE) capital efficiency.
In options market volatility and institutional positioning, LVTX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 49% Vol realized risk). By comparison, CELU carries 116.6% implied volatility (50th %ile, Balanced (25th–60th %ile)), a 3.60x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.01β · 135% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.